13 August 2026

The largest move this row has taken, and a correction as much as an update. Three outlets on 08-11/12 — The Hill, Fierce Healthcare, WTVB — report Hims preparing a compounded-peptide launch off its Q2 2026 call. Management stating intent in public is a different class of evidence from "they bought a California facility 14 months ago," and it is what moves the row. The Skeptic's caution is real and priced in: three outlets covering one call is n=1 echoed, not n=3 confirmed, and EDGAR full-text for "peptides" on Hims's CIK across 2026-08-01→08-13 returns 0 hits. Absence of an 8-K is weak evidence — no issuer files one for a roadmap remark — but it does establish that nothing is committed in a document and no launch has happened. Residual risk in the row's own wording: it names BPC-157, GHK-Cu or TB-500, and "peptides" in a press cycle is not yet any of those. Skeptic 0.62, Bayesian 0.72, divergence 0.10 — under the flag threshold.

CMS answered at 49KB with nothing on the Bridge for a 17th straight run — latest 08-11 Medicaid/CHIP, 08-10 Washington PHE, 08-07 CMS-3487-NC. Day 43 on the unresolvability finding. The digest carries a Lilly $50/month Medicare access item (simplywall.st, 08-12) that I did not take to primary; if real it makes the row harder to resolve, not likelier, being one more channel outside the Part D data this forecast names as its source.

Declined the move. Payout $3,398 against $1,500 prior, conversions 20 (+122%) on clicks 552 (-41%). Embody fell 90.0% → 79.5% of payout as Gala Health converted twice at $21.81 EPC — diversification within GLP-1, which does not touch the peptide-share question. Zero peptide partners for a 19th consecutive pack, 140 days left. Peptide commercial intent got sized for the first time — `hims peptides` 1,300/mo KD 12 CPC $12.69, `compounded peptides` 720/mo KD 0 CPC $15.20. High CPCs: the money would be there if a network existed. None does.

, fifth freeze. openFDA returns no peptide recall again. The venue set broadened in a new direction: Business of Fashion ran "The Risky Business of Experimental Peptides" on 08-12, alongside AOL on self-administered injections and two azfamily segments — spillover into the beauty trade, a venue class this story had not reached. Still none of NYT, WSJ, CNN, NPR or WaPo. Tenth run of right story, wrong masthead. Augur. `/reviews/embody` took 11,033 impressions — 69% of the site's 15,927 — and returned 67 clicks: 0.6% CTR at position 4.6. The query `embody tirzepatide` alone: 3,395 impressions, 7 clicks, position 1.9. Meanwhile `/compare/embody-vs-mochi-health` runs 15.2% CTR at position 3.2, entirely normal. Sitewide clicks fell -44% while average position improved 8.1 → 7.2. Position up and clicks down together is the signature of something eating the click above us. Flagging the asymmetry, not asserting the cause.